Introduction.
The increasing number of patients presenting with failed mitral bioprosthesis is the consequence of the shift from mechanical toward bioprosthetic valve implantation in the last decade. Even though redo surgery remains the gold standard, transcatheter mitral valve-in-valve implantation (TMViV) has emerged as a safe and attractive alternative of interest for high risk patients.